Symyx Technologies, Inc. has acquired Camarillo, CA-based Integrity Biosolution, LLC in an all-cash transaction. IntegrityBio is a leader in contract formulation research and analytical services, providing high-quality, cost-effective formulation and stability solutions for large molecule biopharmaceuticals along with Good Manufacturing Practices (GMP) fill/finish services for Phase 1 and 2 clinical trial volumes. Specific terms of the acquisition were not disclosed.
The acquisition expands Symyx’s Research Service offerings in life sciences into biologic formulations, complementing its existing chemical formulations services.
“The acquisition of IntegrityBio is another milestone in the growth of Symyx Research Services for Life Sciences, and it enables Symyx to offer customers a highly competitive formulation service in biologics,” said Isy Goldwasser, CEO of Symyx. “We can leverage our expertise in informatics and automated parallel experimentation to improve the consistency, accuracy, data capture capabilities and quality of reporting within this market. This is an important change in formulation outsourcing.”
Dr. Byeong Chang, IntegrityBio’s Founder who will continue to oversee technical and operational functions as Chief Scientific Officer, added, “IntegrityBio and Symyx share a successful track record of delivering world-class pharmaceutical product development services, providing our clients the freedom to achieve better results and the ability to manufacture best quality drug products for their clinical trials and commercialization. Together, IntegrityBio and Symyx will be at the forefront of large molecule contract formulation research and clinical fill/finish services. I’m excited at the opportunities this combination will provide us to better serve our customers.”
Release date: August 14, 2008
Source: Symyx Technologies, Inc.
Filed Under: Drug Discovery
